Who has been buying Angio Lab stock?

1 distinct insiders have filed 34 disclosed insider purchases in Angio Lab (251280), most recently on 2024-04-25. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Angio Lab have?

Angio Lab has 34 buy-side and 0 sell-side disclosures on record, covering ₩42M ($29K) in total reported value, spanning 2024-03-20 to 2024-04-25.

Where does StockDrifts get Angio Lab insider data?

From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Angio Lab 251280

Company

안지오랩Angio Lab

Insiders

Buys

Total Value

₩42M ($29K)

Avg Return

-31.82%

Last Filing

2024-04-25

Angio Lab (251280) has 34 disclosed insider purchases and 0 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩42M ($29K) in reported transaction value. The earliest filing StockDrifts holds for Angio Lab is dated 2024-03-20; the most recent is 2024-04-25. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is -31.82%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-08-11	BUY	Market Buy	김민영 Minyoung Kim	CEO	1.6K	₩1,795	+18.4%	₩3M ($2K)
2026-08-06	BUY	Market Buy	김민영 Minyoung Kim	CEO	9.7K	₩1,900	+11.8%	₩20M ($14K)
2024-04-25	BUY	Market Buy	이태식 Taesik Lee	Planning Director	127	₩6,090	-59.4%	₩773K ($537)
2024-04-25	BUY	Market Buy	이태식 Taesik Lee	Planning Director	123	₩6,090	-59.4%	₩749K ($520)
2024-04-03	BUY	Market Buy	이태식 Taesik Lee	Planning Director	33	₩3,750	-34.0%	₩124K ($86)
2024-04-03	BUY	Market Buy	이태식 Taesik Lee	Planning Director	10	₩3,750	-34.0%	₩38K ($26)
2024-04-03	BUY	Market Buy	이태식 Taesik Lee	Planning Director	7	₩3,750	-34.0%	₩26K ($18)
2024-04-02	BUY	Market Buy	이태식 Taesik Lee	Planning Director	5	₩4,000	-38.1%	₩20K ($14)
2024-04-02	BUY	Market Buy	이태식 Taesik Lee	Planning Director	59	₩4,000	-38.1%	₩236K ($164)
2024-04-02	BUY	Market Buy	이태식 Taesik Lee	Planning Director	15	₩4,000	-38.1%	₩60K ($42)
2024-04-02	BUY	Market Buy	이태식 Taesik Lee	Planning Director	40	₩4,000	-38.1%	₩160K ($111)
2024-04-02	BUY	Market Buy	이태식 Taesik Lee	Planning Director	21	₩4,000	-38.1%	₩84K ($58)
2024-04-02	BUY	Market Buy	이태식 Taesik Lee	Planning Director	60	₩4,000	-38.1%	₩240K ($167)
2024-03-26	BUY	Market Buy	이태식 Taesik Lee	Planning Director	10	₩3,495	-29.2%	₩35K ($24)
2024-03-26	BUY	Market Buy	이태식 Taesik Lee	Planning Director	20	₩3,495	-29.2%	₩70K ($49)
2024-03-26	BUY	Market Buy	이태식 Taesik Lee	Planning Director	3	₩3,495	-29.2%	₩10K ($7)
2024-03-26	BUY	Market Buy	이태식 Taesik Lee	Planning Director	57	₩3,495	-29.2%	₩199K ($138)
2024-03-26	BUY	Market Buy	이태식 Taesik Lee	Planning Director	10	₩3,495	-29.2%	₩35K ($24)
2024-03-26	BUY	Market Buy	이태식 Taesik Lee	Planning Director	10	₩3,495	-29.2%	₩35K ($24)
2024-03-26	BUY	Market Buy	이태식 Taesik Lee	Planning Director	58	₩3,495	-29.2%	₩203K ($141)
2024-03-26	BUY	Market Buy	이태식 Taesik Lee	Planning Director	10	₩3,495	-29.2%	₩35K ($24)
2024-03-26	BUY	Market Buy	이태식 Taesik Lee	Planning Director	10	₩3,495	-29.2%	₩35K ($24)
2024-03-26	BUY	Market Buy	이태식 Taesik Lee	Planning Director	10	₩3,495	-29.2%	₩35K ($24)
2024-03-26	BUY	Market Buy	이태식 Taesik Lee	Planning Director	10	₩3,495	-29.2%	₩35K ($24)
2024-03-22	BUY	장외매수	이태식 Taesik Lee	Planning Director	20.3K	₩3,700	-33.1%	₩75M ($52K)
2024-03-22	BUY	장외매수	이태식 Taesik Lee	Planning Director	20.6K	₩3,700	-33.1%	₩76M ($53K)
2024-03-21	BUY	Market Buy	이태식 Taesik Lee	Planning Director	300	₩3,495	-29.2%	₩1M ($728)
2024-03-21	BUY	Market Buy	이태식 Taesik Lee	Planning Director	601	₩3,495	-29.2%	₩2M ($1K)
2024-03-21	BUY	Market Buy	이태식 Taesik Lee	Planning Director	1	₩3,495	-29.2%	₩3K ($2)
2024-03-20	BUY	Market Buy	이태식 Taesik Lee	Planning Director	108	₩3,295	-24.9%	₩356K ($247)
2024-03-20	BUY	Market Buy	이태식 Taesik Lee	Planning Director	1.0K	₩3,295	-24.9%	₩3M ($2K)
2024-03-20	BUY	Market Buy	이태식 Taesik Lee	Planning Director	1.7K	₩3,295	-24.9%	₩6M ($4K)
2024-03-20	BUY	Market Buy	이태식 Taesik Lee	Planning Director	339	₩3,295	-24.9%	₩1M ($776)
2024-03-20	BUY	Market Buy	이태식 Taesik Lee	Planning Director	188	₩3,295	-24.9%	₩619K ($430)
2024-03-20	BUY	Market Buy	이태식 Taesik Lee	Planning Director	2.0K	₩3,295	-24.9%	₩7M ($5K)
2024-03-20	BUY	Market Buy	이태식 Taesik Lee	Planning Director	460	₩3,295	-24.9%	₩2M ($1K)
2024-03-20	BUY	Market Buy	이태식 Taesik Lee	Planning Director	5.0K	₩3,295	-24.9%	₩16M ($11K)
2024-03-20	BUY	Market Buy	이태식 Taesik Lee	Planning Director	100	₩3,295	-24.9%	₩330K ($229)

Frequently asked questions

Who has been buying Angio Lab stock?: 1 distinct insiders have filed 34 disclosed insider purchases in Angio Lab (251280), most recently on 2024-04-25. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Angio Lab have?: Angio Lab has 34 buy-side and 0 sell-side disclosures on record, covering ₩42M ($29K) in total reported value, spanning 2024-03-20 to 2024-04-25.
Where does StockDrifts get Angio Lab insider data?: From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Angio Lab. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.